Transitioning between views
Loading the next view
Pulling the latest page data and restoring the context around your last step.
Still working on it — slow network or a cold server. You can wait, or refresh.
Pulling the latest page data and restoring the context around your last step.
Still working on it — slow network or a cold server. You can wait, or refresh.
BANKBARODA traded between roughly ₹65 and ₹110 from late 2018 through Jun 2022. Four years of flat price, falling slowly relative to private banks, written off by retail as "PSU = dead money." Then something changed at the group level — SBIN, PNB, CANBK, UNION BANK all began climbing together, and the 150-day MA on each one of them turned up within the same eight-week window.
That is what a sector rotation looks like at the moment of inflection. The single stock chart is ambiguous. The basket chart is not. Stage 2 entries on five out of five public-sector banks inside one quarter are not a coincidence — they are a re-rating event happening to the category itself.
On the way up, BANKBARODA looked like a stock-pick. From the inside it was the opposite: PSU bank as a category was inheriting the next leg of credit growth — corporate capex, government infrastructure, falling NPA ratios — and any one name in the basket was going to participate. The sector regime told you what to own; relative strength told you which one to overweight. BANKBARODA happened to have the cleanest setup score; SBIN had the cleanest float; the trade was alive across the whole basket.
In US frameworks Healthcare is the canonical defensive sector — earnings stable across the business cycle. On NSE the same label hides a problem: large-cap pharma exporters carry direct USFDA regulatory risk. A single Form 483 observation or warning letter on a Halol or Visakhapatnam plant can take 15–25% off the stock in a session. That episodic concentration risk makes NSE pharma feel cyclical even though the underlying domestic-formulation revenue isn't.
The compromise here: we keep Healthcare in the Defensive bucket for cycle-positioning reads because the bucket is about which sector category leads when growth slows. But on individual-stock work the USFDA calendar matters more than the macro cycle — and the rotation tables surface plant-level event risk separately in the industry view. Two reads, same data.
Defensive-leads-late, cyclical-leads-early is the textbook account. It works in periods when monetary tightening, recession, recovery, and expansion line up as four clean phases. On NSE those phases are noisier — and three structural features make the standard rotation read miss more than it catches.
Public-sector banks, defence PSUs, oil-marketing companies, NTPC and Coal India don't respect the cyclical/defensive split. Their re-ratings are driven by policy windows — Budget tax simplification, FDI relaxation, asset-quality-cleanup completion, dividend payout rules. The 2022-2024 PSU bank run was a category-wide re-rating with no analogue in US-style sector taxonomy. If you waited for "cyclical leadership" to confirm before buying BANKBARODA, you waited until ₹220.
Defence post-Galwan, EMS post-PLI scheme, capital markets post-demat boom, railway capex post-Vande Bharat — every 12 to 18 months a new narrative pulls capital into a thin slice of one or two industries that nominally sit inside an unfashionable sector. The sector-level tape stays mixed while the industry-level tape rips. Reading at sector altitude alone, you miss it.
US-style frameworks treat Healthcare as defensive — and in domestic terms (formulations, hospitals, diagnostics) it is. But the large-cap NSE pharma exporters (Sun, DRREDDY, AUROPHARMA, ZYDUSLIFE, LUPIN) carry direct USFDA exposure: one Form 483 observation or a warning letter on a single plant can take 15-25% off a stock in a session. The sector behaves defensively in cycle-up phases and cyclically through regulatory windows — same data, two reads, depending on where you are in the FDA inspection calendar.
Add in F&O ban list distortions during expiry weeks, ASM-stage moves on micro-caps, and the monthly settlement rhythm, and the "mechanical" read of NSE sectors loses real signal. Use the model as a starting frame, then look at the live deltas and the industry cuts to see what actually rotated.
Stan Weinstein's 1988 framework was built on US sector indices and a five-day trading week. The categories travel well; the signatures don't. Six patterns recur on NSE that don't appear in Secrets for Profiting in Bull and Bear Markets — and reading rotation without them is reading half the tape.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Health Care | 51.97% | -7.57% | 45.48% | 33.57% | -10.89% |
| Materials | 95.58% | 16.65% | 42.37% | 20.62% | -7.95% |
| Industrials | 87.52% | 31.48% | 82.38% | 45.29% | -9.33% |
| Energy | 73.44% | 21.21% | 81.98% | 34.99% | -10.29% |
| Financials | 75.75% | 16.33% | 47.37% | 28.14% | 1.63% |
| Consumer Staples | 59.96% | 51.72% | 27.42% | 12.54% | 5.8% |
| Consumer Discretionary | 99.91% | 24.28% | 48.17% | 32.41% | -4.2% |
| Utilities | 160.88% | 1.07% | 66.25% | 41.24% | 1.06% |
| Information Technology | 163.57% | 7.32% | 78.36% | 46.68% | -17.89% |
| Real Estate | 112.64% | 3.19% | 54.36% | 50.62% | -19.93% |
| Communication Services | 164.09% | 11.01% | 28.94% | 25.6% | -22.48% |
Stage 2 share is a level — useful for framing where a sector sits in the cycle. The 20-day delta is the rate of change — useful for finding where leadership is moving now. The actionable rotation signal is the delta, ranked across all sectors, with the share of acceleration alongside as a kinetics check.
Read this top-down. The Lead block tells you where new exposure is forming. The Lag block tells you where to underweight or short-pair against. The acceleration column is the kinetics check — a high delta with low acceleration means the sector inherited Stage 2 stocks from a prior move; a high delta with high acceleration means new names are entering Stage 2 right now. The PSU bank Jun-Nov 2022 setup was the second pattern: rising delta and rising acceleration for six weeks running before the breakout confirmed.
NSE Sectoral Indices group 11 broad themes. The underlying NSE industry classification sits at roughly 70 finer cuts. The PSU-vs-Private-Bank split is the clearest example of why industry altitude often matters more than sector altitude — both sit inside "Financials" on the sector table, but they trade as different assets.
| PSU Bank | Private Bank | |
|---|---|---|
| Representative names | SBIN, BANKBARODA, PNB, CANBK | HDFCBANK, ICICIBANK, AXISBANK, KOTAKBANK |
| Earnings driver | Corporate capex book, NPA cleanup | Retail deposit franchise, NIM |
| Rate cycle response | Leads when repo falls | Defends when repo rises |
| Re-rating catalyst | Asset-quality milestones, dividend rules | Subsidiary IPO, fee-income mix |
| Ownership | Govt majority, retail / DII float | FII heavy, free float |
| 2022-2024 leg | +150 to 240% basket return | Flat to +30% basket return |
Today the same logic applies at industry altitude. The five industries with the highest Stage 2 share right now are listed below — most of them sit inside sectors that look mid-pack at the headline level.
A sector at +18% S2-delta over twenty days is interesting. An industry at +35% S2-delta inside an otherwise flat sector is more interesting — that's where concentrated capital is rebuilding leadership without the sector-level tape giving it away yet. The industry view ranks all of them by the same delta.
The hardest period for a sector-rotation read is a narrative-driven rally. Stage 2 share climbs at the basket level because everyone is buying the same theme, but the underlying earnings story isn't yet there. When the narrative breaks, the basket unwinds together — same way it rose — and the rotation signal turns negative right at the moment retail is most committed.
Pharma in 2020-2021 is the textbook NSE example. The COVID molecule-supply story turned Indian pharma exporters into a momentum trade — Merck's molnupiravir contract sent DIVISLAB from ~₹2,100 in Jul 2020 to a peak in the ~₹5,400 region by late 2021. The sector printed Stage 2 share above 60% for most of that window. By mid-2022 the narrative had rotated, US generic prices were compressing, and the same basket lost a year of gains in months. The 30-week MA broke before the Q4 results — the chart told you first.
The same divergence has flagged the 2024 defence-PSU exhaustion, the 2023 capital-markets-stock peak, and the late-2024 EMS slowdown. Rotation reads work best when level and acceleration agree; they fail loudest when level is bull and acceleration is fading.
On 8 Jul 2026, the live tape on NSE points to Health Care as the lead sector at +15.4 on the 20-day Δ inside a BULL_RISING regime running 26 sessions. The interpretation framework below works the same in every regime — what shifts is the action column.
None of this is a buy signal. The rotation read tells you which side of the boat to sit on; the setup-level work tells you which stock to enter and at what price. The trader who skipped the rotation read paid ₹220 for BANKBARODA in 2024 — the trader who read the basket in late 2022 paid ₹110.